Andy Blauvelt, MD, MBA, Owner of Blauvelt Consulting, LLC, in Annapolis, MD, reviews new five-year data highlighting the efficacy of tralokinumab (Adbry, LEO Pharma) in atopic dermatitis (AD). Dr. Blauvelt presented the studies at the recent 2025 European Academy of Dermatology and Venereology (EADV) Congress in Paris, France.
